Nevin Abernethy - Anteo Diagnostics Insider

Anteo Diagnostics Limited -- Australia Stock  

AUD 0.015  0.001  7.14%

Chief Product Development and Research Officer

Dr. Nevin Abernethy Ph.D. is Chief Product Development and Research Officer of Anteo Diagnostics Limited. He was awarded his PhD in animal physiology by the University of Toronto Canada in 1989. After working as a Research Officer and lecturer at the University of Melbournes Department of Veterinary and PreClinical Sciences he moved to Auckland New Zealand where he was a Research Fellow in the Department of Molecular Medicine at the University of Auckland prior to joining Genesis Research and Development Corporationration at the time the biotech company in New Zealand. Nevin is named as an inventor on a number of patents in the area of therapeutics and immunological diseases has published numerous peer reviewed papers in related areas and has demonstrated in product development programs similar to those of interest to BioLayer.
  Executive Since 2007      
61 7 3219 0085

Management Efficiency

The company has return on total asset (ROA) of (2.66) % which means that it has lost $2.66 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (68.77) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 697.44 K in total debt with debt to equity ratio (D/E) of 11.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Anteo Diagnostics Limited has Current Ratio of 1.15 suggesting that it is in a questionable position to pay out its financial obligations in time and when they become due.

Similar Executives

Showing few of many executives


Stephen McIntoshRio Tinto Limited
Tara DinesBHP Billiton Limited
Carla CollingwoodCommonwealth Bank of Australia
Gerard FlorianAustralia and New Zealand Banki
Annabel SpringCommonwealth Bank of Australia
Bold BaatarRio Tinto Limited
Rebecca LimWestpac Banking Corporation
Adam BennettCommonwealth Bank of Australia
Joanne FarrellRio Tinto Limited
Michael LiarakosAustralia and New Zealand Banki
Fred OhlssonAustralia and New Zealand Banki
Bernard RonchiCSL Limited
Taryn MortonCommonwealth Bank of Australia
Hugo BagueRio Tinto Limited
Vera KirikovaRio Tinto Limited
JeanSebastien JacquesRio Tinto Limited
David WhiteingCommonwealth Bank of Australia
Edward BaileyCSL Limited
Megan PepperBHP Billiton Limited
Andrew HardingRio Tinto Limited
Kelly RosmarinCommonwealth Bank of Australia

Entity Summary

Anteo Diagnostics Limited engages in developing, commercializing, manufacturing, and distributing products for the life sciences, clinical diagnostics, and bioseparations markets. Anteo Diagnostics Limited is based in Eight Mile Plains, Australia. Anteo Diagnostics is traded on Australian Securities Exchange in Australia.Anteo Diagnostics Limited (ADO) is traded on Australian Securities Exchange in Australia. It is located in 4/26 Brandl Street and employs 99 people.

Did you try this?

Run Pair Correlation Now

Pair Correlation

Compare performance and examine historical correlation between any two equity instruments
Hide  View All  NextLaunch Pair Correlation
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Anteo Diagnostics Limited to your portfolio

Top Management

Anteo Diagnostics Limited Leadership Team
Nobuyoshi Maeji, Executive, Ph.D
Alan Studley, Director, CPA
Mark Bouris, Chairman
Peter HardingSmith, CFO
Matthew Sanderson, Director
John Hurrell, Director, Ph.D
Stefan Enderling, CEO, Ph.D
Geoffrey Cumming, CEO
Tamara Mills, COO
Julien McInally, Executive, CPA
Shane Hartwig, Executive
Nevin Abernethy, Executive
Richard Martin, Director
Jef Vangenechten, CEO, Ph.D
Rolf Sickman, Director
Sandra Andersen, Director, CPA

Stock Performance

Anteo Diagnostics Performance Indicators